March Biosciences
Manufacturing · Texas, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
7255 Helix Parke Ave Ste 300, Houston, T...Website
march.bioRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About March Biosciences
March Biosciences, Inc is a clinical-stage cell therapy company with a mission to transform patient care in the most challenging hematological malignancies. March Bio's lead asset is at the end of Phase I trials for T-cell malignancies, diseases with a dismal prognosis that is currently unaddressed by CAR-T and targeted therapy technologies. The company's pipeline is designed to expand on these early successes to more broadly impact other high-challenge cancers.Explore more
March Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is March Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when March Biosciences launches new products
Click to see if March Biosciences had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if March Biosciences has recently received funding, and reach out quickly before it becomes old news!
March Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if March Biosciences is spiking on competitors!
Funding: Get notified immidiatlly once March Biosciences has new funding data
Congratulate Masked Content for being promoted to Masked Content at March Biosciences
Earning: See what the market has to say on March Biosciences recently announced quarterly report
Recommended Actions
Find VP level buyers at March Biosciences
Find 2 more new buyers
Compare Similar Companies to March Biosciences
Compare insights from companies similar to March Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
March Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
March Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about March Biosciences.
March Biosciences financials insights
Gather financial insights about March Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Other Financing Round
$4.8M
2024
Series A
$28M
March Biosciences Tech Stack
A closer look at the technologies used by March Biosciences
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Funding
Project
Spending/Investment, Funding
Funding
Funding
Funding
March Biosciences News & Media
March Biosciences Designates Dr. Gurpreet Ratra as Chief Business Officer
By Karen Roman March Biosciences said it appointed Gurpreet Ratra, Ph.D., as Chief Business Officer. Dr. Ratra has more than 25 years of experience in the life science industry including cell and gene therapy, as well as equity research leadership, the company stated. He previously served in companies such as Kate Therapeutics, Skyline TX and Spark […]March Biosciences Announces Appointment of Gurpreet Ratra, Ph.D., as Chief Business Officer
Biotech veteran with over 25 years of business development, strategy and operational experience joins March Bio’s management teamMarch Biosciences Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for MB-105 in Relapsed/Refractory CD5-Positive T-Cell Lymphoma
HOUSTON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), a clinical stage biotechnology company developing cell therapies for hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to MB-105, the Company’s first-in-class autologous CD5-targeted CAR-T cell therapy, in development for relapsed/refractory CD5-positive T-cell lymphoma.March Biosciences Announces Oral Presentation of MB-105 Interim Phase 2 Clinical Data at American Society of Hematology Annual Meeting
HOUSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, today announced that interim clinical data from its ongoing Phase 2 trial of MB-105 will be presented during an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, being held December 6-9, 2025, in Orlando, Florida.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding March Biosciences
Sign Up For FreeTo access detailed company insights
March Biosciences, Inc is a clinical-stage cell therapy company with a mission to transform patient care in the most challenging hematological malignancies. March Bio's lead asset is at the end of Phase I trials for T-cell malignancies, diseases with a dismal prognosis that is currently unaddressed by CAR-T and targeted therapy technologies. The co... Read More
